{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T20:10:09Z","timestamp":1746303009274,"version":"3.40.4"},"reference-count":28,"publisher":"Spandidos Publications","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.3892\/or.2014.3326","type":"journal-article","created":{"date-parts":[[2014,7,11]],"date-time":"2014-07-11T12:36:35Z","timestamp":1405082195000},"page":"1211-1217","source":"Crossref","is-referenced-by-count":4,"title":["The novel bis-benzylisoquinoline PY35 reverses P-glycoprotein-mediated multidrug resistance"],"prefix":"10.3892","volume":"32","author":[{"given":"ZHONGLIAN","family":"CAO","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"MEREDITH","family":"WRIGHT","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"JIEKAI","family":"CHENG","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"XIAOXING","family":"HUANG","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"LI","family":"LIU","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"LIXING","family":"WU","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"PING","family":"YANG","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2014,7,11]]},"reference":[{"key":"key20180107205625_b1-or-32-03-1211","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1038\/nrc3599","article-title":"Cancer drug resistance: an evolving paradigm","volume":"13","author":"Holohan","year":"2013","journal-title":"Nat Rev Cancer"},{"key":"key20180107205625_b2-or-32-03-1211","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1146\/annurev.med.53.082901.103929","article-title":"Mechanisms of cancer drug resistance","volume":"53","author":"Gottesman","year":"2002","journal-title":"Annu Rev Med"},{"key":"key20180107205625_b3-or-32-03-1211","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/nrd1984","article-title":"Targeting multidrug resistance in cancer","volume":"5","author":"Szakacs","year":"2006","journal-title":"Nat Rev Drug Discov"},{"key":"key20180107205625_b4-or-32-03-1211","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1054\/bjoc.2001.2165","article-title":"Mechanism of sensitization of MDR cancer cells by Pluronic block copolymers: selective energy depletion","volume":"85","author":"Batrakova","year":"2001","journal-title":"Br J Cancer"},{"key":"key20180107205625_b5-or-32-03-1211","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/S0022-3565(24)29254-5","article-title":"Mechanism of pluronic effect on P-glycoprotein efflux system in blood-brain barrier: contributions of energy depletion and membrane fluidization","volume":"299","author":"Batrakova","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"key":"key20180107205625_b6-or-32-03-1211","doi-asserted-by":"crossref","first-page":"157","DOI":"10.3109\/07853899509031953","article-title":"The genetic basis of resistance to cancer chemotherapy","volume":"27","author":"Woodhouse","year":"1995","journal-title":"Ann Med"},{"key":"key20180107205625_b7-or-32-03-1211","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/BF02110701","article-title":"Cellular drug efflux and reversal therapy of cancer","volume":"28","author":"Wigler","year":"1996","journal-title":"J Bioenerg Biomembr"},{"key":"key20180107205625_b8-or-32-03-1211","doi-asserted-by":"crossref","first-page":"4805","DOI":"10.1021\/jm030183a","article-title":"Multidrug resistance reversal agents","volume":"46","author":"Robert","year":"2003","journal-title":"J Med Chem"},{"key":"key20180107205625_b9-or-32-03-1211","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1002\/med.20239","article-title":"Overcoming tumor multidrug resistance using drugs able to evade P-glycoprotein or to exploit its expression","volume":"32","author":"Nobili","year":"2012","journal-title":"Med Res Rev"},{"key":"key20180107205625_b10-or-32-03-1211","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0928-0987(00)00114-7","article-title":"Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs","volume":"11","author":"Krishna","year":"2000","journal-title":"Eur J Pharm Sci"},{"key":"key20180107205625_b11-or-32-03-1211","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/0014-5793(93)80403-H","article-title":"Differential inhibition by cyclosporins of primary-active ATP-dependent transporters in the hepatocyte canalicular membrane","volume":"333","author":"B\u00f6hme","year":"1993","journal-title":"FEBS Lett"},{"key":"key20180107205625_b12-or-32-03-1211","first-page":"1128","article-title":"Dose-dependent effects of PSC 833 on its tissue distribution and on the biliary excretion of endogenous substrates in rats","volume":"26","author":"Song","year":"1998","journal-title":"Drug Metab Dispos"},{"key":"key20180107205625_b13-or-32-03-1211","first-page":"3944","article-title":"P-glycoprotein and cytochrome P-450 3A inhibition: dissociation of inhibitory potencies","volume":"59","author":"Wandel","year":"1999","journal-title":"Cancer Res"},{"key":"key20180107205625_b14-or-32-03-1211","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1002\/1097-0142(20010915)92:6<1577::AID-CNCR1484>3.0.CO;2-H","article-title":"A Phase I study of infusional vinblastine in combination with the P-glycoprotein antagonist PSC 833 (valspodar)","volume":"92","author":"Bates","year":"2001","journal-title":"Cancer"},{"key":"key20180107205625_b15-or-32-03-1211","first-page":"802","article-title":"The multidrug resistance modulator valspodar (PSC 833) is metabolized by human cytochrome P450 3A. Implications for drug-drug interactions and pharmacological activity of the main metabolite","volume":"26","author":"Fischer","year":"1998","journal-title":"Drug Metab Dispos"},{"key":"key20180107205625_b16-or-32-03-1211","first-page":"1610","article-title":"The P-glycoprotein antagonist PSC 833 increases the plasma concentrations of 6alpha-hydroxypaclitaxel, a major metabolite of paclitaxel","volume":"7","author":"Kang","year":"2001","journal-title":"Clin Cancer Res"},{"key":"key20180107205625_b17-or-32-03-1211","doi-asserted-by":"crossref","first-page":"298","DOI":"10.2174\/156800909788166619","article-title":"Design of new drug molecules to be used in reversing multidrug resistance in cancer cells","volume":"9","author":"Mayur","year":"2009","journal-title":"Curr Cancer Drug Targets"},{"key":"key20180107205625_b18-or-32-03-1211","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1021\/jm8012745","article-title":"N,N-bis(cyclohexanol)amine aryl esters: a new class of highly potent transporter-dependent multidrug resistance inhibitors","volume":"52","author":"Martelli","year":"2009","journal-title":"J Med Chem"},{"key":"key20180107205625_b19-or-32-03-1211","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.2174\/156802610792928031","article-title":"N,N-bis(cyclohexanol)amine aryl esters: the discovery of a new class of highly potent inhibitors of transporter-dependent multidrug resistance (MDR)","volume":"10","author":"Teodori","year":"2010","journal-title":"Curr Top Med Chem"},{"key":"key20180107205625_b20-or-32-03-1211","first-page":"137","article-title":"Recent advances in the research of P-glycoprotein inhibitors","volume":"2","author":"Yang","year":"2008","journal-title":"Biosci Trends"},{"key":"key20180107205625_b21-or-32-03-1211","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1177\/107327480301000207","article-title":"Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting P-glycoprotein","volume":"10","author":"Thomas","year":"2003","journal-title":"Cancer Control"},{"key":"key20180107205625_b22-or-32-03-1211","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/nrc2789","article-title":"ABC transporters in cancer: more than just drug efflux pumps","volume":"10","author":"Fletcher","year":"2010","journal-title":"Nat Rev Cancer"},{"key":"key20180107205625_b23-or-32-03-1211","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1016\/S0021-9258(18)69196-3","article-title":"Interaction of tetrandrine with slowly inactivating calcium channels. Characterization of calcium channel modulation by an alkaloid of Chinese medicinal herb origin","volume":"263","author":"King","year":"1988","journal-title":"J Biol Chem"},{"key":"key20180107205625_b24-or-32-03-1211","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/0024-3205(94)00952-X","article-title":"Tetrandrine: a new ligand to block voltage-dependent Ca(2+) and Ca(+)-activated K(+) channels","volume":"56","author":"Wang","year":"1995","journal-title":"Life Sci"},{"key":"key20180107205625_b25-or-32-03-1211","first-page":"1102","article-title":"Potential role of tetrandrine in cancer therapy","volume":"23","author":"Chen","year":"2002","journal-title":"Acta Pharmacol Sin"},{"key":"key20180107205625_b26-or-32-03-1211","first-page":"1385","article-title":"Rapid functional assay for the detection of multidrug-resistant cells using the fluorescent dye rhodamine 123","volume":"78","author":"Ludescher","year":"1991","journal-title":"Blood"},{"key":"key20180107205625_b27-or-32-03-1211","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/S0959-8049(01)00356-2","article-title":"The multidrug resistance of tumour cells was reversed by tetrandrine in vitro and in xenografts derived from human breast adenocarcinoma MCF-7\/adr cells","volume":"38","author":"Fu","year":"2002","journal-title":"Eur J Cancer"},{"key":"key20180107205625_b28-or-32-03-1211","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0022-1759(83)90303-4","article-title":"Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays","volume":"65","author":"Mosmann","year":"1983","journal-title":"J Immunol Methods"}],"container-title":["Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/spandidos-publications.com\/10.3892\/or.2014.3326\/download","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T19:34:38Z","timestamp":1746300878000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.spandidos-publications.com\/10.3892\/or.2014.3326"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7,11]]},"references-count":28,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2014,7,11]]},"published-print":{"date-parts":[[2014,9]]}},"alternative-id":["10.3892\/or.2014.3326"],"URL":"https:\/\/doi.org\/10.3892\/or.2014.3326","relation":{},"ISSN":["1021-335X","1791-2431"],"issn-type":[{"type":"print","value":"1021-335X"},{"type":"electronic","value":"1791-2431"}],"subject":[],"published":{"date-parts":[[2014,7,11]]}}}